Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study (Q36000000)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

0 references

Chemoembolization

0 references

hepatocellular carcinoma

0 references

0 references

0 references

author name string

Wang-De Hsiao

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Cheng-Yuan Peng

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Po-Heng Chuang

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hsueh-Chou Lai

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Ken-Sheng Cheng

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jen-Wei Chou

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yang-Yuan Chen

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Cheng-Ju Yu

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Chun-Lung Feng

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Wen-Pang Su

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sheng-Hung Chen

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jung-Ta Kao

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

27 April 2016

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

BMC Gastroenterology

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

50

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Sorafenib and triptolide as combination therapy for hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Management of hepatocellular carcinoma: An update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Current strategy for staging and treatment: the BCLC update and future prospects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Angiogenesis and hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

2 October 2017

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

23 September 2018

Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

23 September 2018

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

23 September 2018

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

23 September 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4847248

23 September 2018

https://api.crossref.org/works/10.1186%2FS12876-016-0464-X

21 January 2018

Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27117280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27117280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27117280

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12876-016-0464-X

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36000000&oldid=2198054577"